Has Grace McComsey received payments from drug or device companies?

Yes. Drug and device makers reported $123,159 in general payments to Grace McComsey across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Grace McComsey did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Grace McComsey come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Grace McComsey

Infectious Disease · Cleveland, OHNPI 1720004336

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $114,230 of the $123,159 with a category attached, or 92.7%. 7 manufacturers reported payments, led by Gilead at 23.4% of the total. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,159in general payments, 2019–2025

Across 92 payments — averaging $1338.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$29K
GSK$28K
Viiv Healthcare Company$21K
Merck$19K
Janssen Products, LP$12K
Theratechnologies Inc.$10K
plus $4K from 1 others

$928,802in research payments, 2019–2025

Across 169 payments — averaging $5495.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Roche Diagnostics Operations, Inc.$237K
Hoffmann-la Roche Limited$208K
Pfizer$193K
Tetraphase Pharmaceuticals, Inc.$101K
Vanda Pharmaceuticals Inc.$97K
Astellas Pharma Global Development$43K
plus $51K from 2 others

What the payments were for

Consulting fees$114,23093%
Speaking & faculty fees$6,0005%
Travel & lodging$2,1412%
Food & beverage$3730%
Education$4160%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	23	$28,869
GSK	11	$27,661
Viiv Healthcare Company	10	$21,353
Merck	18	$18,908
Janssen Products, LP	17	$12,300
Theratechnologies Inc.	9	$10,455
Janssen Scientific Affairs, LLC	4	$3,613

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Symtuza$15,913
Biktarvy$5,040
DELSTRIGO$4,275
EGRIFTA$4,158
MK-8591A$3,850
MK-8591$1,225

How this compares

$123,159 in reported general payments places this provider in the 95th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	59	$260,235
CabenuvaCabotegravir/Rilpivirine	19	$118,775
TivicayDolutegravir Sodium	29	$64,090
DescovyEmtricitabine/Tenofov Alafenam	24	$53,003
Lamivudine	12	$658
Omeprazole	20	$250
Atorvastatin Calcium	35	$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Descovy	$28,869	$313,23883 claims
Viiv Healthcare CompanyCabenuva, Tivicay	$21,353	$182,86448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Cleveland

Melissa JenkinsCleveland$127K
Steven GordonCleveland$78K
Alan TaegeCleveland$76K
Benigno RodriguezCleveland$58K
Robin JumpCleveland$52K
Elie SaadeCleveland$32K
David CanadayCleveland$24K
George YendewaCleveland$19K
Kyle BrizendineCleveland$17K
Michael LedermanCleveland$15K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →